Fulgent Genetics Inc (FLGT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fulgent Genetics Inc (FLGT) has a cash flow conversion efficiency ratio of 0.007x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($7.10 Million) by net assets ($1.04 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Fulgent Genetics Inc to measure how much of total assets are equity-financed.
Fulgent Genetics Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Fulgent Genetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Fulgent Genetics Inc (FLGT) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Fulgent Genetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fulgent Genetics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Miquel y Costas & Miquel S.A.
MC:MCM
|
0.049x |
|
Ambassador Hotel Ltd
TW:2704
|
0.009x |
|
VP Bank AG
SW:VPBN
|
-0.989x |
|
First Business Financial Services
NASDAQ:FBIZ
|
0.008x |
|
Nanfang Black Sesame Group Co Ltd
SHE:000716
|
0.049x |
|
GEOPARK LTD. DL -001
F:G6O
|
0.223x |
|
Beijing Dinghan Tech Co
SHE:300011
|
-0.015x |
|
Matas A/S
CO:MATAS
|
0.111x |
Annual Cash Flow Conversion Efficiency for Fulgent Genetics Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Fulgent Genetics Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see FLGT stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.11 Billion | $-101.64 Million | -0.092x | -592.40% |
| 2024-12-31 | $1.13 Billion | $21.06 Million | 0.019x | -21.72% |
| 2023-12-31 | $1.13 Billion | $27.00 Million | 0.024x | -88.07% |
| 2022-12-31 | $1.27 Billion | $253.52 Million | 0.200x | -56.78% |
| 2021-12-31 | $1.17 Billion | $538.58 Million | 0.462x | +87.04% |
| 2020-12-31 | $569.39 Million | $140.63 Million | 0.247x | +270.57% |
| 2019-12-31 | $82.78 Million | $5.52 Million | 0.067x | +616.11% |
| 2018-12-31 | $52.27 Million | $-675.00K | -0.013x | -152.42% |
| 2017-12-31 | $54.03 Million | $1.33 Million | 0.025x | -69.53% |
| 2016-12-31 | $54.48 Million | $4.41 Million | 0.081x | +142.94% |
| 2015-12-31 | $5.15 Million | $-969.00K | -0.188x | +92.79% |
| 2014-12-31 | $1.68 Million | $-4.40 Million | -2.611x | -- |
About Fulgent Genetics Inc
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pa… Read more